Actualités

Penumbra received FDA clearance for its Thunderbolt stroke thrombectomy device. Boston Scientific (NYSE:BSX) previously agreed to acquire Penumbra, with closing expected later this year. The clearance adds another device to the neurovascular and mechanical thrombectomy portfolio that Boston Scientific is set to own. For investors watching Boston Scientific, the Penumbra deal centers on expanding exposure to neurovascular care and stroke intervention. Thunderbolt now arrives as an FDA...

Analysts remain relatively more upbeat, but this could prove fleeting.

Penumbra’s computer assisted vacuum thrombectomy platform uses aspiration for clot removal during acute ischemic stroke treatment.

The stroke treatment could contribute about $100 million in incremental revenue over time to Boston Scientific, the buyer of Penumbra, one analyst said.

Insightful Moves in Elfun Trusts (Trades, Portfolio)' First Quarter 2026 N-PORT Filing

With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 lowest forward P/E stocks in the S&P 500. Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority […]

Boston Scientific (BSX) concluded the recent trading session at $48.34, signifying a -1.27% move from its prior day's close.

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman […]

The planned logistics site, near a principal manufacturing facility, will handle global distribution of Boston Scientific’s medical devices.

Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million […]

Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated […]

In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...

Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated: Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and […]

Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.

Boston Scientific enters this update cycle with no changes to its current price target, leaving expectations exactly where analysts previously set them. With no new analyst commentary on the stock, the story is less about fresh opinions and more about how existing views are holding steady for now. Ahead, you will see how to track this kind of quiet reset and what it can signal as the narrative around Boston Scientific continues to evolve. Stay updated as the Fair Value for Boston Scientific...

Boston Scientific (NYSE:BSX) reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The trial assessed safety and effectiveness of SEISMIQ 4CE in treating severely calcified coronary artery disease, a complex area of interventional cardiology. This clinical milestone relates to Boston Scientific's coronary portfolio and has not been the focus of recent coverage that centered on Watchman and product...

Boston Scientific has considerably underperformed its sector peers recently, yet analysts remain highly optimistic about the stock’s prospects.

Boston Scientific was down about 0.7% at close, while Lowe's Companies ended the session 3% lower, and Conagra Brands fell by about 1.3%.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best and worst performers in the medical devices & supplies - diversified industry.

Quanta Services, Roblox, and Boston Scientific announced share buybacks totaling $6 billion, each under different market conditions and for different strategic reasons.

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. An Investing Club member sought Cramer’s advice about choosing the best medical equipment maker out of the three: Abbott Labs, Boston Scientific, and Medtronic. He replied: Boston Scientific had a very […]

Medtronic plc (NYSE:MDT) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. Cramer highlighted the company’s share price performance, as he said: Wednesday morning, Medtronic reports. Speaking of jarring, this long-term winner’s become a short-term loser with the stock down 23% year to date. […]

Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform. This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth […]

Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.

Medtronic has underperformed the Nasdaq Composite, and analysts remain somewhat optimistic about the stock’s outlook.

Analyst downgrades, weak outlooks, and management changes added pressure.

Boston Scientific (BSX) stock has been under pressure after management flagged slowing growth in its Watchman heart implant business, a key contributor to earnings. The company reaffirmed full year guidance and is facing fresh competition in left atrial appendage closure. See our latest analysis for Boston Scientific. The sharp reset in expectations for Watchman growth has coincided with a steep share price selloff, with the stock down 37.1% over three months and the 1 year total shareholder...